About Gerbera
/ˈdʒʊr.ber.ah/
Gerbera is a clinical stage pharmaceutical private company focused primarily on developing the best pharmacotherapies in treating CNS indications such as mood and neurological disorders.
The company was founded in 2020 by a serial and successful entrepreneur, Dr. CM Chen.
We are guided on patient-oriented principles, motivated to bring the best-in-class medicines to CNS patients. Our unique and proprietary platform is able to convert endogenous neurosteroids into pharmacotherapies to address unmet medical needs in the CNS field. Our fast-paced clinical development program is based on providing the right therapy to the target patient population.
Our strategy is to develop therapies using the follow methodologies：
We are patient–oriented principles motivated to bringing the best-in-class medicines to CNS patients
Unique and proprietary platform that converts endogenous neurosteroids to unmet medical needs
Fast-pacing clinical development based on targeting precise population
Management Team
Chih-Ming Chen Ph.D.
President & Founder
Chih-Ming Chen Ph.D.
President & Founder
Dr. Chen is Founder and Chairman of Gerbera Therapeutics. He is also Founder, Chairman, and President of TWi Pharmaceuticals, which was sold to Bora Pharmaceuticals in 2022. In 2003, Dr. Chen founded Anchen Pharmaceuticals in Irvine, California which was acquired by Par Pharmaceutical in 2011. Prior to Anchen, he was co-Founder and President of Andrx Pharmaceuticals which was acquired by Watson in 2006. He also worked at Bristol Laboratories, Berlex Laboratories, and IVAX, playing a leading role in R&D from 1982 to 1992. Dr. Chen received his Ph.D. in Pharmaceutics/ Pharmaceutical Chemistry from Ohio State University and his M.S. and B.S. from the School of Pharmacy, National Taiwan University.